Abstract: The invention relates to the utilization of an extract or of extracts, of lipophilic extracts as well as hydrophilic extracts from the fruit of the plant Pandanus conoideus for production of topical preparations for the treatment of diseases of skin and of the mucous membrane in the region of the nose, eyes and/or ears, and in particular for treating of dry skin, neurodermatitis, dermatitis, eczemas, psoriasis, metabolic disorders of the skin, acne, damaged skin, symptoms of skin aging and for smoothing the skin, increasing the skin's hydration and for the treatment and prophylaxis of neurodermatitis, dermatitis, eczemas, and psoriasis.

Abstract: The present invention relates to novel uridine esters of the general formula wherein R represents a carboxylic acid residue, preferably a fatty acid residue and R? represents hydrogen or a hydroxy group, their use as pharmaceutically active agents against a variety of diseases, methods for the preparation of said uridine esters and pharmaceutical compositions containing at least one uridine ester as active ingredient. The present invention relates also to a drug combination comprising free fatty acids and/or fatty acid esters and uridine, deoxyuridine, uridine monophosphate and/or deoxyuridine monophosphate, and to the use of such a drug combination.

Abstract: The present invention relates to plasters for prophylaxis and/or treatment of a dysfunction or disorder of nails, especially onychomycosis, onychocryptosis, nail psoriasis, melanonychia striata, and onychodystrophy, the use of said plasters and methods for prophylaxis and/or treatment of a dysfunction or disorder of nails using said plasters. Said dysfunction or disorder of nails may be induced or caused by drugs, systemic diseases, chemical compounds, physical influences, fungal, yeast, or bacterial infection of the nails and/or the nail beds, or in the context of skin diseases. The plasters show good therapeutically effects on said dysfunction or disorder of nails without the need of drilling a hole into the nail and/or daily scraping of the nail. Preferred embodiments of the plasters consist of an occlusive backing layer and a layer attached to said backing layer. The layer comes in close contact with the nail and optionally with the surrounding skin.

Abstract: The present invention relates to novel uridine esters of the general formula (I) wherein R represents a carboxylic acid residue, preferably a fatty acid residue and R? represents hydrogen or a hydroxy group, their use as pharmaceutically active agents against a variety of diseases, methods for the preparation of said uridine esters and pharmaceutical compositions containing at least one uridine ester as active ingredient. The present invention relates also to a drug combination comprising free fatty acids and/or fatty acid esters and uridine, deoxyuridine, uridine monophosphate and/or deoxyuridine monophosphate, and to the use of such a drug combination.

Abstract: The present invention relates to novel uridine esters of the general formula wherein R represents a carboxylic acid residue, preferably a fatty acid residue and R? represents hydrogen or a hydroxy group, their use as pharmaceutically active agents against a variety of diseases, methods for the preparation of said uridine esters and pharmaceutical compositions containing at least one uridine ester as active ingredient. The present invention relates also to a drug combination comprising free fatty acids and/or fatty acid esters and uridine, deoxyuridine, uridine monophosphate and/or deoxyuridine monophosphate, and to the use of such a drug combination.

Abstract: The present invention relates to novel uridine esters of the general formula wherein R represents a carboxylic acid residue, preferably a fatty acid residue and R? represents hydrogen or a hydroxy group, their use as pharmaceutically active agents against a variety of diseases, methods for the preparation of said uridine esters and pharmaceutical compositions containing at least one uridine ester as active ingredient. The present invention relates also to a drug combination comprising free fatty acids and/or fatty acid esters and uridine, deoxyuridine, uridine monophosphate and/or deoxyuridine monophosphate, and to the use of such a drug combination.

Abstract: The invention relates to the compounds (2R,4R), (2S,4R)-2-methylthiazolidine-2,4-dicarboxylic acid and (2RS,4R)-2-methylthiazolidine-2,4-dicarboxylic acid and salts of said compounds, the use thereof for the prophylaxis and/or treatment of neurodegenerative diseases, methods for the prophylaxis and/or treatment of neurodegenerative diseases, and pharmaceutical compositions containing said compounds together with physiologically compatible carriers, auxiliary agents, and/or solvents.

Abstract: The invention relates to the compounds (2R,4R), (2S,4R)-2-methylthiazolidine-2,4-dicarboxylic acid and (2RS,4R)-2-methylthiazolidine-2,4-dicarboxylic acid and salts of said compounds, the use thereof for the prophylaxis and/or treatment of neurodegenerative diseases, methods for the prophylaxis and/or treatment of neurodegenerative diseases, and pharmaceutical compositions containing said compounds together with physiologically compatible carriers, auxiliary agents, and/or solvents.

Abstract: The invention relates to the compounds (2R,4R), (2S,4R)-2-methylthiazolidine-2,4-dicarboxylic acid and (2RS,4R)-2-methylthiazolidine-2,4-dicarboxylic acid and salts of said compounds, the use thereof for the prophylaxis and/or treatment of neurodegenerative diseases, methods for the prophylaxis and/or treatment of neurodegenerative diseases, and pharmaceutical compositions containing said compounds together with physiologically compatible carriers, auxiliary agents, and/or solvents.

Abstract: Use of 2-methyl-thiazolidine-2,4-dicarboxylic acid (2-MTDC) and/or its physiologically tolerable salts for the treatment and/or prevention of cancer.

Abstract: Use of 2-methyl-thiazolidine-2,4-dicarboxylic acid (2-MTDC) and/or its physiologically tolerable salts for the treatment and/or prevention of cancer.

Abstract: The invention relates to the compounds (2R,4R), (2S,4R)-2-methylthiazolidine-2,4-dicarboxylic acid and (2RS,4R)-2-methylthiazolidine-2,4-dicarboxylic acid and salts of said compounds, the use thereof for the prophylaxis and/or treatment of neurodegenerative diseases, methods for the prophylaxis and/or treatment of neurodegenerative diseases, and pharmaceutical compositions containing said compounds together with physiologically compatible carriers, auxiliary agents, and/or solvents.

Abstract: The invention relates to a method for producing a recombinant functional plasminogen in micro-organisms, and to a method for identifying plasminogen activators. The nucleic acid sequence coding for the fuctional part of the plasminogen is fused with a nucleic acid molecule coding for at least one signal peptide. The nucleic acid molecule coding for the plasminogen and the nucleic acid molecule coding for the signal peptide are combined with codons for interfaces of proteases which ensure the separation of the signal peptide. The recombinant plasminogen or the corresponding plasmin is suitable for treating wounds which are slow to heal or not healing, by application of the enzyme in an appropriate formulation.

Abstract: The present invention relates to novel uridine esters of the general formula wherein R represents a carboxylic acid residue, preferably a fatty acid residue and R? represents hydrogen or a hydroxy group, their use as pharmaceutically active agents against a variety of diseases, methods for the preparation of said uridine esters and pharmaceutical compositions containing at least one uridine ester as active ingredient. The present invention relates also to a drug combination comprising free fatty acids and/or fatty acid esters and uridine, deoxyuridine, uridine monophosphate and/or deoxyuridine monophosphate, and to the use of such a drug combination.

Abstract: The present invention relates to novel uridine esters of the general formula wherein R represents a carboxylic acid residue, preferably a fatty acid residue and R? represents hydrogen or a hydroxy group, their use as pharmaceutically active agents against a variety of diseases, methods for the preparation of said uridine esters and pharmaceutical compositions containing at least one uridine ester as active ingredient. The present invention relates also to a drug combination comprising free fatty acids and/or fatty acid esters and uridine, deoxyuridine, uridine monophosphate and/or deoxyuridine monophosphate, and to the use of such a drug combination.

Abstract: The present invention relates to novel uridine esters of the general formula wherein R represents a carboxylic acid residue, preferably a fatty acid residue and R? represents hydrogen or a hydroxy group, their use as pharmaceutically active agents against a variety of diseases, methods for the preparation of said uridine esters and pharmaceutical compositions containing at least one uridine ester as active ingredient. The present invention relates also to a drug combination comprising free fatty acids and/or fatty acid esters and uridine, deoxyuridine, uridine monophosphate and/or deoxyuridine monophosphate, and to the use of such a drug combination.

Abstract: The present invention relates to plasters for prophylaxis and/or treatment of dysfunctions or disorders of nails and/or nail growth, the use of said plasters and methods for prophylaxis and/or treatment of a dysfunction or disorder of nails and/or nail growth using said plasters. A preferred embodiment of the plaster consists of an occlusive backing layer and a contact layer attached to said backing layer. The contact layer comes in close contact with the nail and optionally with the surrounding skin. The contact layer is made of a adhesive, a skin and/or nail permeation enhancer, a therapeutically effective amount of a pharmaceutically active agent, and suitable additives.

Abstract: The present invention relates to plasters for prophylaxis and/or treatment of dysfunctions or disorders of nails, especially onychomycosis, onychocryptosis, nail psoriasis, melanonychia striata, and onychodystrophy, the use of said plasters and methods for prophylaxis and/or treatment of a dysfunction or disorder of nails using said plasters. Said dysfunction or disorder of nails may be induced or caused by drugs, systemic diseases, chemical compounds, physical influences, fungal, yeast, or bacterial infection of the nails and/or the nail beds, or in the context of skin diseases. The plaster shows good therapeutically effects on said dysfunction or disorder of nails without the need of drilling a hole into the nail and/or daily scraping of the nail. A preferred embodiment of the plaster consists of an occlusive backing layer and a contact layer attached to said backing layer. The contact layer comes in close contact with the nail and optionally with the surrounding skin.

Abstract: The present invention relates to plasters for prophylaxis and/or treatment of a dysfunction or disorder of nails, especially onychomycosis, onychocryptosis, nail psoriasis, melanonychia striata, and onychodystrophy, the use of said plasters and methods for prophylaxis and/or treatment of a dysfunction or disorder of nails using said plasters. Said dysfunction or disorder of nails may be induced or caused by drugs, systemic diseases, chemical compounds, physical influences, fungal, yeast, or bacterial infection of the nails and/or the nail beds, or in the context of skin diseases. The plasters show good therapeutically effects on said dysfunction or disorder of nails without the need of drilling a hole into the nail and/or daily scraping of the nail. Preferred embodiments of the plasters consist of an occlusive backing layer and a layer attached to said backing layer. The layer comes in close contact with the nail and optionally with the surrounding skin.

Abstract: The present invention relates to novel uridine esters of the general formula (I) wherein R represents a carboxylic acid residue, preferably a fatty acid residue and R′ represents hydrogen or a hydroxy group, their use as pharmaceutically active agents against a variety of diseases, methods for the preparation of said uridine esters and pharmaceutical compositions containing at least one uridine ester as active ingredient. The present invention relates also to a drug combination comprising free fatty acids and/or fatty acid esters and uridine, deoxyuridine, uridine monophosphate and/or deoxyuridine monophosphate, and to the use of such a drug combination.